ClickCease

Novartis to pay $347 million to settle SEC and DOJ charges of foreign bribes in Greece Vietnam and South Korea

The Securities and Exchange Commission today announced that Novartis AG, a global pharmaceutical and healthcare company headquartered in Basel, Switzerland, has agreed to pay over $112 million to settle charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA). The SEC’s order finds that local subsidiaries or affiliates of Novartis or its former subsidiary Alcon Inc. engaged in schemes to make improper payments or to provide benefits to public and private healthcare providers in South Korea, Vietnam, and Greece in exchange for prescribing or using Novartis or Alcon products. According to the order, these schemes took place between 2012 and 2016 and were known among certain managers of the local subsidiaries or affiliates. The order also finds that Novartis lacked sufficient internal accounting controls within its former Alcon business in China from 2013 to 2015, which used forged contracts as part of local financing arrangements that generated large losses and resulted in Novartis and Alcon writing off more than $50 million in bad debt.

Novartis consented to the entry of an order requiring the company to cease and desist from committing violations of the books and records and internal accounting controls provisions of the FCPA. Novartis agreed to pay disgorgement of $92.3 million and $20.5 million in prejudgment interest and to comply with a three-year undertaking to self-report on the status of its remediation and implementation of compliance measures. In addition, subsidiaries of Novartis and Alcon entered into deferred prosecution agreements with the U.S. Department of Justice and have agreed to pay more than $233 million in criminal fines. The SEC’s investigation was conducted by Sonali Singh and Regina Barrett and supervised by Tracy L. Price. The SEC appreciates the assistance of the U.S. Department of Justice Criminal Division’s Fraud Section, the U.S. Attorney’s Office for the District of New Jersey, the Federal Bureau of Investigation, the Swiss Financial Market Supervisory Authority, and the United Kingdom Financial Conduct Authority.

Novartis settled U.S. charges of violating the Foreign Corrupt Practices Act, bribing foreign health workers to use Novartis products.

The DoJ’s fine is $233.9 million.

Jeffrey Newman represents whistleblowers nationwide including cases involving SEC whistleblower and foreign bribes. He can be reached at jeff@jeffnewmanlaw.com or at 978-880-4758

Website developed in accordance with Web Content Accessibility Guidelines 2.0.
If you encounter any issues while using this site, please contact us: 800.682.7157